IL3RA and acute myeloid leukemia: They exposed a humanized mice model bearing MOLM-13Luc AML cells to 2.5 mg/kg AZA for three doses, and 24 h after the last dose mice were treated with CD123 CAR-T cells, resulting in a lower tumor burden and longer survival on the AZA-treated group.